KUWAIT DRUGS

 

SEARCH

 

SUGGESTIONS

 

ADD PRODUCTS

 

HOME

0-9    A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

 

 

PREVIOUS

  

NEXT

 
 

SALIPAX 20 MG CAPSULES

 

 
 

 

GENERIC NAMES

MANUFACTURERS 

MEDICAL GROUP

MEDICAL ARTICLES

 

DRUGS IN :

 

 

FDA DRUGS

UNITED STATES

CANADA

UNITED KINGDOM

AUSTRALIA

GERMANY

FRANCE

MIDDLE EAST

KUWAIT

LEBANON

EGYPT

SYRIA

BAHRAIN

IRAN

JORDAN

SAUDI ARABIA

UNITED ARAB EMIRATES

 

 

 
 

SIZE:

20 MG

 

GENERIC NAME:

FLUOXETINE

 

MANUFACTURER:

MEPHA LTD.

 

UNIT:

 

ADMINISTRATION ROUTE:

 

FDA PREGNANCY GROUP:

C

 

INDICATIONS:

Bulimia nervosa

Depression

Obsessive compulsive disorder

Panic disorder

Premenstrual dysphoric disorder

 

SIDE EFFECTS:

vomiting

weight gain

weight loss

menstrual pain

photosensitivity

vasodilation

yawning

Agitation

anxiety

dizziness

fatigue

headache

malaise

nausea

sweating

vertigo

Akathisia

sexual dysfunction, including abnormal ejaculation

anorgasmia

decreased libido

genital anesthesia (rare)

impotence

skin rash, hives, or itching

Chills or fever

joint or muscle pain

Abnormal bleeding

breast enlargement or pain

dyspnea

galactorrhea

hypoglycemia

hyponatremia

mania or hypomania

movement disorders

palpitation

seizures

serotonin syndrome

Anxiety or nervousness

anorexia

asthenia

diarrhea

drowsiness

headache

increased sweating

insomnia

nausea

tremor

Abnormal dreams

alopecia

changes in vision

chest pain

dizziness or lightheadedness

frequent urination

gastrointestinal effects, including change in sense of taste

constipation

dryness of mouth

increased appetite

stomach cramps, gas, or pain

 

ABSOLUTE CONTRAINDICATIONS :

 

RELATIVE CONTRAINDICATIONS :

Diabetes mellitus

>> Hepatic function impairment

Neurological impairment, including developmental delay

Seizures

Parkinson's disease

Renal function impairment

Sensitivity to fluoxetine

Weight loss

 

ADULT DOSE:

Antidepressant or Antiobsessional agent or Premenstrual dysphoric disorder -Oral, initially 20 mg (base) a day as a single morning dose . The dose may be increased as needed and tolerated at intervals of four to eight weeks . Note: Some clinicians begin fluoxetine therapy with a single morning dose of 5 to 10 mg (base) . The manufacturer states that, in the treatment of depression or obsessive-compulsive disorder, doses over 20 mg (base) a day may be taken as a single morning dose or in two divided doses, in the morning and at noon . Antibulimic agent-Oral, the target dose is 60 mg (base) a day as a single morning dose . Patients may need to be titrated up to this dose over several days . Note: For all indications, patients with hepatic function impairment should receive a lower dosage or less frequent dosing . Also, for elderly patients and patients who have concurrent illness or who are taking multiple medications, a lower dosage or less frequent dosing should be considered . For patients with renal function impairment, dosage adjustments are not routinely required .

 

MAXIMUM ADULT DOSE:

80 mg (base) a day .

 

PEDIATRIC DOSE:

Safety and efficacy have not been established .  

 

MAXIMUM PEDIATRIC DOSE:

 

ELDERLY DOSE:

Antidepressant or Antiobsessional agent or Premenstrual dysphoric disorder -Oral, initially 20 mg (base) a day as a single morning dose . The dose may be increased as needed and tolerated at intervals of four to eight weeks . Note: Some clinicians begin fluoxetine therapy with a single morning dose of 5 to 10 mg (base) . The manufacturer states that, in the treatment of depression or obsessive-compulsive disorder, doses over 20 mg (base) a day may be taken as a single morning dose or in two divided doses, in the morning and at noon . Antibulimic agent-Oral, the target dose is 60 mg (base) a day as a single morning dose . Patients may need to be titrated up to this dose over several days . Note: For all indications, patients with hepatic function impairment should receive a lower dosage or less frequent dosing . Also, for elderly patients and patients who have concurrent illness or who are taking multiple medications, a lower dosage or less frequent dosing should be considered . For patients with renal function impairment, dosage adjustments are not routinely required .

 

 

PREVIOUS

  

NEXT